Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI
HANAU,
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109007299/en/
Typical niobium-titanium-copper composite superconductors suitable for MRI magnets.
The combined order value of the two agreements is approximately
Bruker’s advanced superconductors also support new helium-free MRI magnet architectures in maintaining demanding field stability and homogeneity requirements. BEST’s world-leading expertise in various LTS and HTS superconducting materials and technologies serves global markets for magnets and other superconducting devices, which are utilized in MRI, Proton Therapy, NMR and EPR spectroscopy, preclinical MRI, magnetic confinement fusion, emerging superconducting wind turbines, high-energy physics, and important other deep-tech superconductivity applications.
“Our OEM customers depend on performance-leading MRI systems that deliver state-of-the-art image quality with minimal downtime and at competitive cost of ownership,” said
About
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with customers, Bruker is enabling innovation and customer success in post-genomic life science molecular and cell biology, in disease biology and translational research, in specialty diagnostics, in applied and biopharma applications, as well as in industrial and cleantech research and QC, and in next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology, molecular diagnostics and therapeutic drug monitoring. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260109007299/en/
Investor Contact:
Director, Investor Relations
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Director, Sales & Marketing
T: +49 173 7599461
E: pr@bruker.com
Source: